Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ZLAB vs IONS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IONS Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

IONS Overall Winner 6-Pillar Tally: ZLAB 3 – 3 IONS Matrix Metrics: ZLAB 4 – 6 IONS

As of Nov 16, 2026, Ionis Pharmaceuticals, Inc. (IONS) is the stronger overall head-to-head candidate over Zai Lab Limited (ZLAB) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ZLAB carries a Unified Composite Score of 47.4/100 (HOLD) at $23.74 (N/M Forward P/E, -63.0% operating margin), whereas IONS carries 63.9/100 (BUY) at $28.57 (90.9x Forward P/E, -58.8% operating margin).

  • Technical & Structure Timing Caution: ZLAB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.1); meanwhile IONS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ZLAB vs IONS
ZLAB NASDAQ
Zai Lab Limited American Depositary Shares
Pharmaceutical Preparations
$23.74
-3.5% 1D
Market Cap $3.0B
TTM Revenue $442M
Forward P/E N/M
Beta / 30D Vol 1.19β · 78% Vol
Unified Composite Score
47.4 / 100 HOLD
Tech 25.0 Fund 39.0 Flow 50.0 Mom 53.5
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.1 · SMA20: $23.97 · SMA50: $24.57
IONS NASDAQ Head-to-Head Winner
Ionis Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$28.57
-1.7% 1D
Market Cap $4.7B
TTM Revenue $960M
Forward P/E 90.9x
Beta / 30D Vol 0.18β · 86% Vol
Unified Composite Score
63.9 / 100 BUY
Tech 60.0 Fund 63.0 Flow 73.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.3%), weak momentum, RSI 24
RSI-14: 23.7 · SMA20: $38.46 · SMA50: $43.07

6-Pillar Scorecard Institutional Category Breakdown (ZLAB 3 – 3 IONS)

Columns: Metric · ZLAB · IONS
1. Valuation Multiples IONS
Forward P/E N/M 90.9x
Trailing P/E N/M 90.9x
PEG Ratio N/M N/M
EV / Revenue 6.8x 6.2x
2. Growth & Scale IONS
Revenue Growth (YoY) -6.8% +54.9%
Earnings Growth (YoY) +0.0% -43.7%
TTM Revenue (USD) $442M $960M
Market Cap $3.0B $4.7B
3. Profitability & Quality IONS
Gross Margin 0.6% 3.0%
Operating Margin -63.0% -58.8%
Net Profit Margin -44.9% -56.9%
Return on Equity (ROE) -30.0% -108.0%
4. Balance Sheet & Cash Flow ZLAB
Cash Generation (TTM) -$262M EBITDA -$623M
Cash Flow Margin -59.3% EBITDA Mgn -64.9%
Net Cash / Leverage $5.01 Book/Sh · -30.0% ROE $1.33B Net Debt (4.14x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ZLAB
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 58.4% (58th %ile) 59.9% (17th %ile)
Put/Call OI Skew Thin ADR Chain 1.81x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat ZLAB
OpEx & R&D Intensity 63.6% of Rev ($281M) 61.8% of Rev ($593M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ZLAB (4) vs IONS (6)
Institutional Metric ZLAB IONS Criterion Row Edge
Market Capitalization
Scale
$3.0B $4.7B Larger Scale IONS
Trailing P/E Ratio
Valuation
N/M 90.9x Lower Multiple IONS
Forward P/E Ratio
Valuation
N/M 90.9x Lower Multiple IONS
Revenue Growth (YoY)
Growth
-6.8% +54.9% Higher Growth IONS
Operating Margin (TTM)
Profitability
-63.0% -58.8% Higher Margin IONS
Net Profit Margin
Profitability
-44.9% -56.9% Higher Margin ZLAB
Return on Equity (ROE)
Capital Efficiency
-30.0% -108.0% Higher ROE ZLAB
52-Week Range Position
Momentum
60% ($16–$29) 2% ($27–$87) Stronger Trend ZLAB
Beta / 30D Volatility
Risk Regime
1.19β · 78% Vol 0.18β · 86% Vol Lower Realized Risk ZLAB
Unified Institutional Score
Composite Signal
47.4 / 100 (HOLD) 63.9 / 100 (BUY) Higher Composite IONS
Trailing 12M Revenue (USD)
Operating Scale
$442M $960M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
0.6% 3.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.8x EV/Rev N/M PEG · 6.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$262M EBITDA ($5.01 Book/Sh · -30.0% ROE) -$623M ($1.33B Net Debt (4.14x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ZLAB +35.85 pp
ZLAB: +2.37% · IONS: -33.48%
3M Horizon ZLAB +44.93 pp
ZLAB: -7.16% · IONS: -52.09%
6M Horizon ZLAB +86.48 pp
ZLAB: +25.87% · IONS: -60.61%
1Y Horizon ZLAB +68.35 pp
ZLAB: +9.25% · IONS: -59.1%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ZLAB vs IONS. Trailing 12-month operating profitability (ZLAB -63.0% vs IONS -58.8%) and valuation multiples (ZLAB N/M vs IONS 90.9x Forward P/E) are benchmarked directly in Pillar 4 below.

ZLAB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$442M
Gross Margin0.6%
Op. Margin-63.0%
ROE / Fwd P/E-30.0% · N/M
IONS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$960M
Gross Margin3.0%
Op. Margin-58.8%
ROE / Fwd P/E-108.0% · 90.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ZLAB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 58.4%
IV Percentile 58th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ZLAB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IONS BREAKDOWN
58d in phase · OBV DISTRIBUTION
Current IV 59.9%
IV Percentile 17th %ile
Put/Call OI Skew 1.81x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact IONS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ZLAB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.0B market capitalization and -63.0% operating margin.
OpEx & R&D Reinvestment 63.6% of Rev ($281M)
90D Engineering Disclosures 0 Published
IONS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.7B market capitalization and -58.8% operating margin.
OpEx & R&D Reinvestment 61.8% of Rev ($593M)
90D Engineering Disclosures 0 Published

Investor FAQ ZLAB vs IONS Key Questions & Quantitative Answers

As of Nov 16, 2026, Ionis Pharmaceuticals, Inc. (IONS) is the stronger overall head-to-head candidate over Zai Lab Limited (ZLAB) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ZLAB carries a Unified Composite Score of 47.4/100 (HOLD) at $23.74 (N/M Forward P/E, -63.0% operating margin), whereas IONS carries 63.9/100 (BUY) at $28.57 (90.9x Forward P/E, -58.8% operating margin). Technical & Structure Timing Caution: ZLAB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.1); meanwhile IONS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IONS leads the Growth & Scale pillar: ZLAB posts -6.8% YoY revenue growth and +0.0% YoY earnings growth on $442M TTM revenue (0.6% gross margin, -63.0% operating margin), compared with IONS at +54.9% YoY revenue growth and -43.7% YoY earnings growth on $960M TTM revenue (3.0% gross margin, -58.8% operating margin). On trailing 12-month operating scale, ZLAB generates $442M in USD-normalized revenue versus $960M for IONS. In operating R&D and SG&A reinvestment, ZLAB deploys 63.6% of Rev ($281M) (0 90-day corporate R&D disclosures) versus 61.8% of Rev ($593M) (0 disclosures) for IONS.

IONS screens cheaper on headline valuation multiples. ZLAB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.8x EV/Revenue (-59.3% EBITDA margin), whereas IONS trades at 90.9x Forward P/E, 90.9x Trailing P/E, N/M PEG, and 6.2x EV/Revenue (-64.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ZLAB (-30.0% ROE) versus IONS (-108.0% ROE) capital efficiency.

In options market volatility and institutional positioning, ZLAB carries 58.4% implied volatility (58th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 78% Vol realized risk). By comparison, IONS carries 59.9% implied volatility (17th %ile, Compressed (<25th %ile)), a 1.81x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.18β · 86% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.